Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 89

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 89
---
 due to an increase in cash received from research
and development tax incentives (from A$1,555,196 to A$4,851,839), partially offset by a decrease in cash received from interest income
(from A$145,035 to A$50,484) and an increase in the payments to suppliers and employees in connection with our clinical trial activities
(from A$25,194,388 to A$28,138,720) and a decrease in receipts from customers (from A$292,359 to A$260,462).

Investing Activities

Net cash used in investing
activities decreased from A$1,530,681 in fiscal 2023 to A$320,000 in fiscal 2024, due to a decrease in payments for equipment and intellectual
property(from A$1,485,375 to nil) and payments for property, plant and equipment (from A$45,306 to nil), partially offset buy payments
for license fees (nil to A$320,000)

Financing Activities

Net cash provided by financing
activities increased from A$9,217,791 in fiscal 2023 to A$30,196,945 in fiscal 2024, due to an increase in the proceeds received from
the issuance of equity securities (from A$10,072,555 to A$29,645,526) and an increase in the proceeds received from borrowings (from nil
to A$7,369,190), partially offset by an increase in the transaction costs related to share issuances (from A$854,764 to A$1,533,771),
an increase in the costs related to loans and borrowings (from nil to A$117,000), and an increase in repayment of borrowings (from nil
to A$5,167,000).

C. Research and Development, Patents and Licenses

For a description of our research
and development programs and activities, see “ Item 4. Information on the Company - B. Business Overview”.

For a description of the amount
spent during each of the last three fiscal years on company-sponsored research and development activities, as well as the components of
our research and development expenses, see note 3(c) to our financial statements for fiscal 2025, 2024 and 2023.

D. Trend Information

One of our primary expenditures
involves research and development costs. Increases or decreases in research and development expenditure are attributable to the level
of clinical